Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334289 | 0.86 | S1PR1 (0.63) | S1PR1CHUKTXNRD1NOX4S1PR3 | |
| SCHEMBL12129286 | 0.85 | S1PR1 (0.43) | S1PR1S1PR3 | |
| SCHEMBL1334839 | 0.84 | S1PR1 (0.51) | S1PR1HDAC1HDAC8HDAC6CHUK | |
| SCHEMBL27855413 | 0.84 | MAPT (0.51) | S1PR1 | |
| SCHEMBL1335722 | 0.84 | S1PR1 (0.62) | S1PR1S1PR3 | |
| SCHEMBL1335167 | 0.82 | S1PR1 (0.49) | S1PR1HDAC1HDAC8HDAC6CHUK | |
| SCHEMBL14237262 | 0.81 | S1PR1 (0.51) | S1PR1S1PR3 | |
| SCHEMBL14696504 | 0.74 | S1PR1 (0.63) | S1PR1HDAC1HDAC8HDAC6CHUK | |
| SCHEMBL1226619 | 0.74 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL1226614 | 0.74 | S1PR1 (0.66) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389509-B2 | Substituted pyrazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389509-B2 | Substituted pyrazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2382211-B1 | PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2382211-B1 | PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-102361868-A | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists | BRISTOL MYERS SQUIBB CO | 2012-02-22 | — | — | CN | disclosed |
| US-20110275610-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110275610-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| EP-2382211-A1 | PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS | Bristol-Myers Squibb Company (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010085584-A1 | PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085584-A1 | PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275610-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | S1PR3, S1PR1, S1PR4 | S1PR1 2/4885HDAC1 1260/4885HDAC8 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.